Form 4: DexCom Director Nicholas Augustinos Sells Over 6,000 Shares Under Pre-Arranged 10b5-1 Plan

DexCom Inc. Director Nicholas Augustinos reported the sale of 6,290 shares of common stock in two transactions in mid-June 2025, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Nicholas Augustinos, a Director of DexCom Inc. (DXCM), reported the sale of 6,290 shares of common stock across two transactions in June 2025.
• On June 13, 2025, Mr. Augustinos sold 2,618 shares at a price of $81.69 per share.
• On June 16, 2025, an additional 3,672 shares were sold at $82.80 per share.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Augustinos on March 14, 2025, designed for the orderly disposition of his shares.
• Following these transactions, Mr. Augustinos beneficially owns 33,411 shares indirectly through the Kirschner/Augustinos Revocable Trust and directly holds 5,046 unvested restricted stock units (RSUs).
• The 5,046 unvested RSUs were granted on May 8, 2025, and are set to vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, the disclosure that these sales were executed under a pre-arranged 10b5-1 plan mitigates concerns, indicating a planned disposition rather than a reaction to adverse company news.

Positives

• The sales were executed under a pre-arranged 10b5-1 plan, indicating a planned disposition rather than a reaction to new, negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the director's direct equity alignment with shareholders.

Risks

• No specific risks related to the company's operations or financial health were mentioned in this Form 4 filing. The inherent risk of insider selling, even if planned, is that it could be misinterpreted by the market.

Future Outlook

The document primarily reports past transactions and existing equity holdings. The only forward-looking information relates to the vesting schedule of 5,046 restricted stock units, which will vest on the earlier of May 8, 2026, or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Management Comments

• "On March 14, 2025, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The shares set forth above were sold pursuant to the 10b5-1 Plan."

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape within the medical device or continuous glucose monitoring (CGM) sector where DexCom operates.

Comparison to Industry Standards

• This document is a standard insider transaction report (Form 4) and does not contain information that allows for a comparison of company performance or results against global benchmarks or specific comparable companies/projects. The reported transactions are specific to an individual's equity management.

Corporate Governance

Related Party Transactions

• Shares are held indirectly by the Kirschner/Augustinos Revocable Trust, with respect to which the reporting person (Nicholas Augustinos) is a trustee. This represents a related party holding.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, slightly reduces the director's direct equity alignment. However, the pre-planned nature minimizes negative signaling.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Vesting of 5,046 unvested restricted stock units on the earlier of May 8, 2026, or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

DexCom Inc., DXCM, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Nicholas Augustinos, Director, Restricted Stock Units, SEC Filing